Pfizer Corporation

Judith L Treadway

Dennis J Hoover

William H Martin

Bernard Hulin

Bruce A Lefker

Philip Albert Carpino

Michael Paul Zawistoski

Lydia Codetta Pan

Charles Kwok-Fung Chiu

Douglas Phillips

W Ross Tracey

Joyce A Sutcliffe

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I,where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and th compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

Treatment of insulin resistance

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein Ris carboxy, (C-C)alkoxycarbonyl, C(O)NRRor C(O)R, useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.

Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein R is carboxy, (C -C )alkoxycarbonyl, C(O)NR R or C(O)R , useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.

Substituted N-( indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Treatment of insulin resistance with growth hormone secretagogues

A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection. 

Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection

Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors

Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as

A method of preventing non-cardiac tissue damage resulting from ischemia and/or hypoxia, comprising administering to a patient in need of such treatment an effective amount of an glycogen phosphorylase inhibitor.

Growing community of inventors

Gales Ferry, CT, United States of America

Judith L Treadway